Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02626364 · ClinicalTrials.gov registry record · Phase 2
Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
A Phase 2 study, sponsored by Arog Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT02626364 is a Phase 2 study that has completed, run by Arog Pharmaceuticals. The registered enrollment target is 11 participants.
The verdict
NCT02626364, a Phase 2 study, has completed, sponsored by Arog Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is a proof of concept, single-arm study to investigate crenolanib monotherapy in patients with recurrent/refractory glioblastoma with PDGFRA gene amplification by assessing the progression-free survival (PFS) at 6 months. Crenolanib will be given orally starting at 100 mg TID continuously until disease progression, unacceptable toxicity, or consent withdrawal.
Interventions
- DRUG crenolanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-04 |
| Est. Completion | 2020-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02626364
The ClinicalTrials.gov registry entry for NCT02626364 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arog Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which crenolanib is the first listed.
NCT02626364 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02626364 about?
NCT02626364 is a clinical study titled "Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification". This is a proof of concept, single-arm study to investigate crenolanib monotherapy in patients with recurrent/refractory glioblastoma with PDGFRA gene amplification by assessing the progression-free survival (PFS) at 6 months. Crenolanib will be given orally starting at 100 mg TID continuously until...
What is the current status of trial NCT02626364?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2016-04. Estimated completion is 2020-07.
What interventions are being tested in trial NCT02626364?
The interventions under investigation include: crenolanib (DRUG).
Who is sponsoring clinical trial NCT02626364?
This trial is sponsored by Arog Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.